58336-10-0

Upstream product

• 4746-97-8 cyclohexanedione monoethylene ketal 
• 38580-68-6 4-hydroxymethyl-cyclohexanone 
• 676-58-4 methylmagnesium chloride 
• 917-54-4 methyllithium 
• 75-16-1 methylmagnesium bromide 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 1489-97-0 ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 
• 59498-98-5 1-Methyl-2-oxabicyclo[2.2.2]octan-3-one 
• 23521-81-5 (1,4-dioxaspiro[4.5]dec-8-yl)methanol 
• 17429-02-6 4-hydroxy-4-methylcyclohexanone 

Downstream Products

• 1443999-15-2 cis-(4-hydroxy-4-methylcyclohexyl)methyl benzoate 
• 1443999-16-3 trans-(4-hydroxy-4-methylcyclohexyl)methyl benzoate 
• 1443999-17-4 cis-[4-(formylamino)-4-methylcyclohexyl]methyl benzoate 
• 1443999-18-5 trans-[4-(formylamino)-4-methylcyclohexyl]methyl benzoate 

Relevant academic research and scientific papers

1-METHYL-4-[(4-PHENYLPHENYL)SULFONYLMETHYL]CYCLOHEXYANOL AND 1-METHYL-4-[[4-(2-PYRIDYL)PHENYL]SULFONYLMETHYL]CYCLOHEXANOL COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylme

Bcl-2 INHIBITORS

Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same.

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

PYRAZOLE AMIDE DERIVATIVE

The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.

Facile synthesis of N-substituted amides from alcohols and amides

A facile and versatile method for preparing N-substituted amides from alcohols and amides using a Bronsted acid and an alkali metal halide has been developed. Treatment of tertiary alcohols and amides in the presence of an alkali metal halide or methanesulfonic acid in trifluoroacetic acid at elevated temperature afforded the corresponding N-substituted amides in moderate to high yields. Tertiary alcohols with various functional groups such as ether, ester, imide, carbamate, and halogen groups were tolerated under these conditions. This method can be used for the efficient and practical synthesis of various N-substituted formamides without the use of unmanageable cyano compounds. Georg Thieme Verlag Stuttgart New York.

Highly efficient conversion of alcohols to isocyanides

Treatment of tertiary alcohols with silver salts (AgClO4, AgBF4, or AgOTf) and trimethylsilyl cyanide (TMSCN), followed by hydrolysis, directly affords excellent yields of corresponding isocyanides. This reaction proceeds selectively